These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 24056819)

  • 1. Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.
    Niewerth D; Franke NE; Jansen G; Assaraf YG; van Meerloo J; Kirk CJ; Degenhardt J; Anderl J; Schimmer AD; Zweegman S; de Haas V; Horton TM; Kaspers GJ; Cloos J
    Haematologica; 2013 Dec; 98(12):1896-904. PubMed ID: 24056819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
    Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
    J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy.
    Niewerth D; Kaspers GJ; Jansen G; van Meerloo J; Zweegman S; Jenkins G; Whitlock JA; Hunger SP; Lu X; Alonzo TA; van de Ven PM; Horton TM; Cloos J
    J Hematol Oncol; 2016 Sep; 9(1):82. PubMed ID: 27599459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors.
    Besse L; Besse A; Kraus M; Maurits E; Overkleeft HS; Bornhauser B; Bourquin JP; Driessen C
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells.
    Roeten MSF; van Meerloo J; Kwidama ZJ; Ter Huizen G; Segerink WH; Zweegman S; Kaspers GJL; Jansen G; Cloos J
    Cells; 2021 Mar; 10(3):. PubMed ID: 33802801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells.
    Kraus M; Rückrich T; Reich M; Gogel J; Beck A; Kammer W; Berkers CR; Burg D; Overkleeft H; Ovaa H; Driessen C
    Leukemia; 2007 Jan; 21(1):84-92. PubMed ID: 17024115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors.
    Downey-Kopyscinski S; Daily EW; Gautier M; Bhatt A; Florea BI; Mitsiades CS; Richardson PG; Driessen C; Overkleeft HS; Kisselev AF
    Blood Adv; 2018 Oct; 2(19):2443-2451. PubMed ID: 30266819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL-AF4 fusion protein.
    Jenkins TW; Downey-Kopyscinski SL; Fields JL; Rahme GJ; Colley WC; Israel MA; Maksimenko AV; Fiering SN; Kisselev AF
    Sci Rep; 2021 May; 11(1):10883. PubMed ID: 34035431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome inhibitors.
    Cvek B
    Prog Mol Biol Transl Sci; 2012; 109():161-226. PubMed ID: 22727422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).
    Niewerth D; Jansen G; Riethoff LF; van Meerloo J; Kale AJ; Moore BS; Assaraf YG; Anderl JL; Zweegman S; Kaspers GJ; Cloos J
    Mol Pharmacol; 2014 Jul; 86(1):12-9. PubMed ID: 24737138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukaemia.
    Szczepanek J; Pogorzala M; Konatkowska B; Juraszewska E; Badowska W; Olejnik I; Kuzmicz M; Stanczak E; Malinowska I; Stefaniak J; Sobol G; Szczepanski T; Czyzewski K; Wysocki M; Styczynski J
    Anticancer Res; 2010 Jun; 30(6):2119-24. PubMed ID: 20651360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim.
    Dai Y; Chen S; Wang L; Pei XY; Kramer LB; Dent P; Grant S
    Br J Haematol; 2011 Apr; 153(2):222-35. PubMed ID: 21375523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia.
    Koyama D; Kikuchi J; Hiraoka N; Wada T; Kurosawa H; Chiba S; Furukawa Y
    Leukemia; 2014 Jun; 28(6):1216-26. PubMed ID: 24301524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression of catalytic proteasome subunits and resistance toward proteasome inhibition of B lymphocytes from patients with primary sjogren syndrome.
    Martinez-Gamboa L; Lesemann K; Kuckelkorn U; Scheffler S; Ghannam K; Hahne M; Gaber-Elsner T; Egerer K; Naumann L; Buttgereit F; Dörner T; Kloetzel PM; Burmester GR; Faustman DL; Feist E
    J Rheumatol; 2013 May; 40(5):663-73. PubMed ID: 23504381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissecting bortezomib: development, application, adverse effects and future direction.
    Cao B; Li J; Mao X
    Curr Pharm Des; 2013; 19(18):3190-200. PubMed ID: 23151134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit.
    Blackburn C; Gigstad KM; Hales P; Garcia K; Jones M; Bruzzese FJ; Barrett C; Liu JX; Soucy TA; Sappal DS; Bump N; Olhava EJ; Fleming P; Dick LR; Tsu C; Sintchak MD; Blank JL
    Biochem J; 2010 Sep; 430(3):461-76. PubMed ID: 20632995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
    Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
    Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
    Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
    Franke NE; Niewerth D; Assaraf YG; van Meerloo J; Vojtekova K; van Zantwijk CH; Zweegman S; Chan ET; Kirk CJ; Geerke DP; Schimmer AD; Kaspers GJ; Jansen G; Cloos J
    Leukemia; 2012 Apr; 26(4):757-68. PubMed ID: 21941364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.
    Huber EM; Groll M
    Angew Chem Int Ed Engl; 2012 Aug; 51(35):8708-20. PubMed ID: 22711561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.